Your guide to AI
By Nathan Benaich, Air Street Capital
subscribers
issues
Resending last weekend's newsletter 🙏
Hi readers, For many of you, last weekend's issue ended up somewhere other than your inbox.Here is the link at which you can safely read the issue in your browser:https://newsletter.airstreet.com/issues/your-guide-to-ai-june-2022-we-re-back-815198For future d…
👋 Your guide to AI: June 2022 (we're back!)
🏥 Life (and) scienceThe public biotech industry, alongside their technology peers, has suffered a sizable erosion of enterprise value as part of the post-covid stock market melt down in 2022. Some 128 biotechs trade at valuations below their cash at hand, sug…
🦄 State of AI Report 2021
In our 2020 Report, we predicted that transformers would cross the chasm from NLP into computer vision, setting new state-of-the-art. The pace of transformer proliferation has been astounding - over 5% of the slides in this report contain transformers!
😎 Your guide to AI: June 2021
🏥 Life (and) scienceIn September last year, I wrote an op ed entitled AI has disappointed on Covid. I made the case that despite lots of hype around drug repurposing, literature mining, and various computer vision-based diagnostics, AI methods hadn’t really m…
🔊 Your guide to AI: May 2021
Signing off, Nathan Benaich, 20 June 2021Air Street Capital | Twitter | LinkedIn | State of AI Report | RAAIS | London.AIAir Street Capital is a venture capital firm investing in AI-first technology and life science companies. We’re an experienced team of inv…
🤓 Your guide to AI: May 2021
🏥 Life (and) scienceOxford-based Exscientia is on a roll: the company announced its third molecule is entering clinical trials in collaboration with Sumitomo Dianippon Pharma. The drug, DSP-0038, is to be used for the treatment of Alzheimer’s disease psychosi…
🔊 Your guide to AI: April 2021
Signing off, Nathan Benaich, 16 May 2021Air Street Capital | Twitter | LinkedIn | State of AI Report | RAAIS | London.AIAir Street Capital is a venture capital firm investing in AI-first technology and life science companies. We’re an experienced team of inve…
🦔Your guide to AI: April 2021
🏥 Life (and) scienceLast time we discussed how computational techniques in drug discovery often focus on very early steps of the value chain and that there are few examples of drugs that made it into clinical testing. Good timing! Exscientia, an Oxford-based …
🔊 Your guide to AI: March 2021
Signing off, Nathan Benaich, 19 April 2021Air Street Capital | Twitter | LinkedIn | State of AI Report | RAAIS | London.AIAir Street Capital is a venture capital firm investing in AI-first technology and life science companies. We’re an experienced team of in…
🐣 Your guide to AI: March 2021
🏥 Life (and) scienceIn his popular column for Science Translational Medicine, Derek Lowe rightly pressed AI developers to “attack the right problems” if they want to have an impact on drug discovery. In short, this means pointing AI to the later stages of dru…
🔊Your guide to AI: a conversation with Cade Metz
Signing off, Nathan Benaich, 21 March 2021Air Street Capital | Twitter | LinkedIn | State of AI Report | RAAIS | London.AIAir Street Capital is a venture capital firm investing in AI-first technology and life science companies. We’re an experienced team of in…
🔊Audio edition of your guide to AI: February 2021
Signing off, Nathan Benaich, 21 March 2021Air Street Capital | Twitter | LinkedIn | State of AI Report | RAAIS | London.AIAir Street Capital is a venture capital firm investing in AI-first technology and life science companies. We’re an experienced team of in…
🌱Your guide to AI: February 2021
🏥 Life (and) scienceContinuing on the theme of reproducible and relevant clinical AI systems, the DECIDE-AI Steering Group proposed a new step that puts AI models through their paces before entering large-scale clinical trials. This is similar to how drugs mu…
❤️ Your guide to AI: January 2021
🏥 Life (and) scienceThe last newsletter issue discussed how AI models in healthcare must learn clinically-relevant tasks. To continue this thread, Xiao (who works on SPIRIT-AI and CONSORT-AI) raised an important point that is easy to forget: improved disease …
☃️ Your guide to AI: December 2020
🏥 Life (and) scienceAI applied to medical imaging continues to be a hot topic in medicine. Last year saw the first Medicare/Medicaid reimbursement approval for a deep learning-based stroke detection system produced by VizAI. This month we saw Paige receive th…
🧬 Your guide to AI: November 2020
🏥 Life (and) scienceLife (and) scienceThese past weeks have been a positive whirlwind for the biotechnology industry and global public health. First, we had the rapid approvals of COVID-19 vaccines, both using mRNA technology (Moderna, BioNTech) and more trad…
🎃 Your guide to AI: October 2020
🏥 Life (and) scienceThe Nobel Prize in Chemistry was awarded to Jennifer Doudna and Emmanuelle Charpentier for the discovery of CRISPR, the popular gene-editing method. Keep your eyes out for machine learning-based improvements to the technology :-)A new pape…
💥State of AI Report 2020: Highlight commentary enclosed!
Open sourcing AI research is important for accountability, reproducibility and driving progress in AI but, in reality, the vast majority of AI research papers are behind corporate lock and key. The industry has not evolved much since 2016 when 90% of research…
🦠My Financial Times opinion piece: "Why AI has disappointed on Covid"
The Financial Times, September 20th 2020Opinion | Artificial intelligence Why AI has disappointed on Covid BY NATHAN BENAICH The writer is a biologist, general partner of Air Street Capital and co-author of State of AI Report In late February, an artificial i…
🔭 Your guide to AI: July 2020
🏥 Healthcare and life scienceA study of scientific publications, patents, company reports for 21 major pharmaceutical companies between 2014 and 2019 concluded that the industry is in an “early mature” phase of using AI in their businesses. Novartis came in f…